A solid-phase extraction-HPLC-UV method was successfully developed and validated for the rapid (<6 min) and cost-effective determination of rivaroxaban in human plasma.
The developed SPE-HPLC-UV method provides a rapid and cost-effective alternative to HPLC-MS-MS for determining rivaroxaban concentrations in human plasma for pharmacokinetic studies.
In this study, a solid-phase extraction (SPE)-high performance liquid chromatography (HPLC)-ultra violet (UV) method was developed for the determination of rivaroxaban (RIV), an oral anticoagulant drug, in human plasma samples. The concentration of RIV in plasma samples was increased 7.5 times and the interference coming from matrix components was avoided by using SPE. The extracted samples of RIV were analyzed by using an HPLC-UV method. RIV was approved in 2008 and many studies have been published in recent years in order to investigate its pharmacokinetic profile in various groups. In light of this information, it is clear that the RIV pharmacokinetic profile should be investigated in further studies; the HPLC-UV method presented in this study might be an easy method to apply, as it is a cheap and rapid alternative to HPLC-MS-MS for this purpose. A Phenomenex Luna 5-µm C18 100 Å LC column (250 × 4.6 mm) was used for the separation of RIV and prednisolone (internal standard). The total analysis time was <6 min. The method was validated according to the FDA guidelines and can be proposed for pharmacokinetic studies of RIV.
Çelebi̇er et al. (Mon,) reported a other. Solid-phase extraction-high performance liquid chromatography-ultra violet (SPE-HPLC-UV) method vs. HPLC-MS-MS was evaluated on Determination of rivaroxaban concentration in human plasma. A solid-phase extraction-HPLC-UV method was successfully developed and validated for the rapid (<6 min) and cost-effective determination of rivaroxaban in human plasma.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: